Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer

Authors: Pablo Sáenz-López, Rafael Carretero, José Manuel Cózar, José Maria Romero, Julia Canton, José Ramón Vilchez, Miguel Tallada, Federico Garrido, Francisco Ruiz-Cabello

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk.

Methods

A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area.

Results

Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09–2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09–2.38). A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. No epistatic effect was found for the combination of different polymorphisms studied. Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms.

Conclusion

Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development.
Literature
1.
2.
Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016/j.ccr.2005.02.013.CrossRefPubMed
3.
Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006, 16: 38-52. 10.1016/j.semcancer.2005.07.006.CrossRefPubMed
4.
De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999, 155: 1985-1992.CrossRefPubMedPubMedCentral
5.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nature Rev. 2007, 7: 256-269. 10.1038/nrc2090.
6.
Nelson WG, De Marzo AM, Isaacs WB: Prostate cancer. N Engl J Med. 2003, 349: 366-381. 10.1056/NEJMra021562.CrossRefPubMed
7.
Platz EA, De Marzo AM: Epidemiology of inflammation and prostate cancer. J Urol. 2004, 171: S36-S40. 10.1097/01.ju.0000108131.43160.77.CrossRefPubMed
8.
Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology. 2002, 60: 78-83. 10.1016/S0090-4295(02)01637-0.CrossRefPubMed
9.
Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002, 13: 72-79. 10.1097/00001648-200201000-00012.CrossRefPubMed
10.
Oh BR, Sasaki M, Perinchery G, Ryu SB, Park YI, Carroll P, Dahiya R: Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol. 2000, 163: 1584-1587. 10.1016/S0022-5347(05)67683-5.CrossRefPubMed
11.
Wu HC, Chang CH, Chen HY, Tsai FJ, Tsai JJ, Chen WC: p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int. 2004, 73: 41-46. 10.1159/000078803.CrossRefPubMed
12.
McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002, 62: 3369-3372.PubMed
13.
Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang WY, Yu K, Calle EE, Jacobs EJ, Chen BE, Andriole GL, Figueroa JD, Yeager M, Platz EA, Michaud DS, Chanock SJ, Thun MJ, Hsing AW: TNF polymorphisms and prostate cancer risk. Prostate. 2008, 68: 400-407. 10.1002/pros.20694.CrossRefPubMed
14.
15.
Conti I, Rollins BJ: CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol. 2004, 14: 149-10.1016/j.semcancer.2003.10.009.CrossRefPubMed
16.
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000, 6: 3282-PubMed
17.
Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002, 62: 1093-PubMed
18.
Antonio Sica, Paola Allavena, Alberto Mantovani: Cancer related inflammation: The macrophage connection. Cancer Leters. 2008, 264: 299-310. 10.1016/j.canlet.2008.01.041.CrossRef
19.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nature Rev. 2007, 7: 256-269. 10.1038/nrc2090.
20.
Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer. 2003, 3: 276-285. 10.1038/nrc1046.CrossRefPubMed
21.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997, 94: 3195-3199. 10.1073/pnas.94.7.3195.CrossRefPubMedPubMedCentral
22.
Mocellin S, Rossi CR, Pilati P, Nitti D: Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005, 16: 35-53. 10.1016/j.cytogfr.2004.11.001.CrossRefPubMed
23.
Dinarello CA: The interleukin-1 family: 10 years of discovery. FASEB J. 1994, 8: 1314-1325.PubMed
24.
25.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000, 404: 398-402. 10.1038/35006081.CrossRefPubMed
26.
Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M: Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003, 37: 65-71. 10.1053/jhep.2003.50017.CrossRefPubMed
27.
Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A: Polymorphisms of the interleukin-1β gene are associated with increased risk of non-small cell lung cancer. Int J Cancer. 2004, 109: 353-356. 10.1002/ijc.11695.CrossRefPubMed
28.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F, Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, tumor necrosis factor-a, NFK B1, andperoxisome proliferator-activated receptor g with colorectal cancer. Cancer Res. 2003, 63: 3560-3566.PubMed
29.
Grimm C, Berger I, Tomovski C, Zeillinger R, Concin N, Leodolter S, Koelbl H, Tempfer CB, Hefler LA: A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis. Gynecol Oncol. 2004, 92: 936-940. 10.1016/j.ygyno.2003.11.039.CrossRefPubMed
30.
Sehouli J, Mustea A, Koensgen D, Chen FC, Lichtenegger W: Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Ann Oncol. 2003, 14: 1501-1504. 10.1093/annonc/mdg413.CrossRefPubMed
31.
Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LM, Biunno I: Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics. 2002, 54: 82-6. 10.1007/s00251-002-0445-9.CrossRefPubMed
32.
Mulé JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ: RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996, 7: 1545-1553. 10.1089/hum.1996.7.13-1545.CrossRefPubMed
33.
Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA: Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006, 4: 726-731. 10.1158/1055-9965.EPI-05-0797.CrossRef
34.
Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ: Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med. 1989, 169: 1449-1459. 10.1084/jem.169.4.1449.CrossRefPubMed
35.
Roth SJ, Carr MW, Springer TA: C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-γ inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol. 1995, 25: 3482-488. 10.1002/eji.1830251241.CrossRefPubMed
36.
Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R: Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem. 2005, 51: 452-455. 10.1373/clinchem.2004.041657.CrossRefPubMed
37.
Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer. 2001, 92: 1085-1091. 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K.CrossRefPubMed
38.
Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T: Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA. 1999, 96: 4581-4585. 10.1073/pnas.96.8.4581.CrossRefPubMedPubMedCentral
39.
Rovin BH, Lu L, Saxena R: A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999, 259: 344-348. 10.1006/bbrc.1999.0796.CrossRefPubMed
40.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997, 94: 3195-3199. 10.1073/pnas.94.7.3195.CrossRefPubMedPubMedCentral
41.
Fraile A, Nieto A, Beraún Y, Vinasco J, Matarán L, Martín J: Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens. 1998, 51: 386-390.CrossRefPubMed
42.
Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Macijewski JP: Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol. 2007, 136: 237-248. 10.1111/j.1365-2141.2006.06429.x.CrossRefPubMed
43.
Ho SY, Wang YJ, Huang PC, Tsai ST, Chen CH, Chen HH, Chang CJ, Guo HR: Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma. J Chin Med Assoc. 2006, 69: 351-357.CrossRefPubMed
44.
Govan VA, Constant D, Hoffman M, Williamson AL: The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006, 26: 24-10.1186/1471-2407-6-24.CrossRef
45.
Gelmann EP: Complexities of prostate-cancer risk. N Engl J Med. 2008, 358: 961-3. 10.1056/NEJMe0708703.CrossRefPubMed
46.
Oliver J, Gómez-García M, Paco L, López-Nevot MA, Piñero A, Correro F, Martín L, Brieva JA, Nieto A, Martín J: A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis. 2005, 11: 576-9. 10.1097/01.MIB.0000161916.20007.76.CrossRefPubMed
47.
Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H: Sequence variants in Toll-like receptor gene cluster (TLR6 -TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst. 2005, 97: 525-532.CrossRefPubMed
48.
Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Grönberg H: Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 2004, 64: 2918-2922. 10.1158/0008-5472.CAN-03-3280.CrossRefPubMed
49.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000, 404: 398-402. 10.1038/35006081.CrossRefPubMed
50.
Hefler LA, Ludwig E, Lebrecht A, Zeillinger R, Tong-Cacsire D, Koelbl H, Leodolter S, Tempfer CB: Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Investig. 2002, 9: 386-90. 10.1016/S1071-5576(02)00177-6.CrossRefPubMed
51.
Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R: Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res. 2005, 11: 5718-21. 10.1158/1078-0432.CCR-05-0001.CrossRefPubMed
52.
Kamangar F, Cheng C, Abnet CC, Rabkin CS: Interleukin-1B polymorphisms and gastric cancer risk–a meta-analysis. Cancer Epidemiol Biomarkers. 2006, 15: 1920-8. 10.1158/1055-9965.EPI-06-0267.CrossRef
53.
Mule JJ, Custer M, Averbook B, et al: Rantes secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996, 7: 1545-53. 10.1089/hum.1996.7.13-1545.CrossRefPubMed
54.
Sánchez E, Sabio JM, Callejas JL, de Ramón E, Garcia-Portales R, García-Hernández FJ, Jiménez-Alonso J, González-Escribano MF, Martín J, Koeleman BP: Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet. 2006, 7: 48-10.1186/1471-2350-7-48.CrossRefPubMedPubMedCentral
55.
Vinasco J, Beraún Y, Nieto A, Fraile A, Mataran L, Pareja E, Martín J: Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens. 1997, 49: 74-8. 10.1111/j.1399-0039.1997.tb02715.x.CrossRefPubMed
56.
Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafé M, Cavallone L, Marchegiani F, Olivieri F, Franceschi C, Caruso C: Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet. 2003, 40: 296-9. 10.1136/jmg.40.4.296.CrossRefPubMedPubMedCentral
57.
Cardelli M, Cavallone L, Marchegiani F, Oliveri F, Dato S, Montesanto A, Lescai F, Lisa R, De Benedictis G, Franceschi C: A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (A/G)-308 polymorphism. J Gerontol A Biol Sci Med Sci. 2008, 63: 454-60.CrossRefPubMed
Metadata
Title
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer
Authors
Pablo Sáenz-López
Rafael Carretero
José Manuel Cózar
José Maria Romero
Julia Canton
José Ramón Vilchez
Miguel Tallada
Federico Garrido
Francisco Ruiz-Cabello
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-382

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Recurrent and multiple bladder tumors show conserved expression profiles

Research article

Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls

Research article

Altered regulation of Prox1-gene-expression in liver tumors

Research article

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

Research article

Pharmacokinetic characteristics and anticancer effects of 5-Fluorouracil loaded nanoparticles

Research article

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits